Predictive medicine company PreMD (Toronto) reported that the license, development and supply agreements with McNeil Consumer Healthcare (McNeil) for PreMD's Prevu Skin Sterol Test will terminate in three months.

As a result, PreMD will reacquire all worldwide rights for the Prevu family of skin sterol tests and said it will pursue other opportunities to commercialize the products. As part of the termination provisions of the agreement, McNeil will continue to support Prevu for a period of three months to ensure transition to PreMD.

"We have been advised by McNeil that there has been a change in their strategic focus" said Dr. Brent Norton, president/CEO of PreMD. "By reacquiring the rights to the Prevu technology, we will realize significantly improved revenue on a per unit basis. We will be evaluating our strategic options for the commercialization of both Prevu POC and Prevu LT and will assess which markets we can manage effectively on our own and in which markets we will pursue partnerships."